Program Goal. Program Goal Current Stroke Guidelines: AHA/ASA.

Slides:



Advertisements
Similar presentations
Addressing the Challenges in Primary and Secondary Stroke Prevention
Advertisements

Strategies to Reduce Door-to-Puncture Times in Acute Stroke
The Latest Lipid Guidelines:
Target: Stroke Honor Roll
Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.
SAVOR-TIMI 53 Summary SAVOR-TIMI 53: Primary End Point of CV Death, MI, Ischemic Stroke.
New ESMO Guidance on Tumor Sidedness in mCRC
Acute Hypertension Management Optimizing Door-to-Needle Time in Ischemic Stroke.
NOACs for Cancer-Associated Thrombosis:
Atrial Fibrillation and PCI
Cardiogenic Shock.
When Is Adding Aspirin to NOACs Worth the Risk?
Heart Rate, HF Admissions, and Readmissions
Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.
Select Topics in Cardiovascular Medicine
Pulmonary Embolism Scope of the Problem Massive vs Submassive Pulmonary Embolism.
Selecting NOACs for High-Risk Patients
The Essentials for Secondary Stroke Prevention
Panelists. Secondary Prevention of Acute Ischemic Stroke: Can We Improve Outcomes?
Counseling Patients About Germline BRCA Mutations
Stroke and AF.
Assessing the Risk for Stroke in Patients With Atrial Fibrillation
A Unified Approach to Anticoagulant Therapy in ACS: What's Missing?
What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?
Dispelling Myths and Misconceptions ACC/AHA 2013 Digoxin Guidelines for Heart Failure.
Treatment Options to Consider
Seizures in the Elderly: Treatment and Special Considerations
Novel Insulin Combinations: What Does the Primary Care Physician Need to Know?
Efficacy and Safety of Edoxaban in Patients With AF and HF
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Antithrombotic Protection in CAD and HF
TAVR and the Risk of Thrombosis
Tackling CV Risk in T2DM.
Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?
What Anticoagulant Registries Are Revealing
Watching for the Patient With AF: Latest Advances and Technologies
Learning Objectives Classification of VTE Goals of VTE Treatment.
Drug-Coated Balloons:
Program Goals Disclaimer Overview Assessing Disease Activity.
Principles of Comparative Effectiveness in PsA and AS
Program Goals Overview Glatiramer Acetate 3 Times a Week.
Atrial Fibrillation.
Jun M, et al. Lancet 2010 Epub May 10
Advancing the Treatment of IBD With Biologics
What's New on Interventions for Lower Limb Spasticity?
Factor Xa Inhibitors in PAD
The Role of IDH Inhibitors in Hematologic Malignancies
Optimizing Outcomes in Crohn Disease
A Guideline-Based Approach to HCV Care
Current Challenges in Managing Hemophilia
Application of Biologics in IBD:
Program Goals Background: Anticoagulation in Patients With VTE.
Factor Xa Inhibitors in Coronary Artery Disease
Clinical Challenges and Updates in Managing Seizure Clusters
Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.
Managing Pain in the 21st Century
5 Good Minutes on Atrial Fibrillation-related Stroke
Selecting Treatment Approaches in Hemophilia
Contemporary Considerations in Biomarker-Guided Therapy
So Many Guidelines, So Little Time:
Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.
Updates on Dyslipidemia
Evaluating the Science of Cardiogenic Shock
Real-World Data in Cardiology: Focus on Atrial Fibrillation
ESC Guideline on the Management of STEMI Recommendation for DAPT
Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.
Improving Management of Acute HTN in Patients With Stroke
Expert Perspectives.
Understanding and Reducing Diagnostic Error
Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?
Presentation transcript:

Program Goal

Current Stroke Guidelines: AHA/ASA

Current Stroke Guidelines: National Quality Forum

Current Stroke Guidelines: ACEP/ANA

Evolution of Data on Use of Thrombolytic Therapy

Evolution of Data: Meta-analyses

Evolution of Data: Meta-analyses (cont)

Evolution of Data (cont)

Controversies of tPA Therapy

Controversies of tPA Therapy (cont): Observational Data

Controversies of tPA Therapy (cont): Bias

Controversies of tPA Therapy (cont): Malpractice

AHA Get With the Guidelines-Stroke Data: Improved Door-to-Needle Times

AHA Get With the Guidelines-Stroke Data: Outcomes

Summary and Key Points

Abbreviations

References

References (cont)

References (cont)

References (cont)